Search

BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangement is a series of mutations of non-small cell lung cancer (NSCLC) patients. Since 2011, multiple ALK inhibitors (ALKis) have been developed and launched for targeted therapy. In this study, we sought to investigate different strategies of sequential applying the ALKis and their clinical benefits to the overall survival (OS). METHODS: A total of 176 patients with advanced NSCLC (stage IIIB–IV) harboring the ALK rearrangement were included in this cohort study. They were diagnosed between February 1, 2012 and November 19, 2019 at Peking University Cancer Hospital. Clinical characters were reviewed from patients’ records. Strategies of drugs, progression-free survival (PFS) and OS were collected during the follow-ups. The Kaplan-Meier method and multivariate Cox proportional-hazard analysis were used to conduct the analyses survival and to examine the relationship between the variables and OS. RESULTS: A significantly longer OS was observed either in patients treated with crizotinib [N=106, median OS (mOS): 32.9 months] or in patients treated with a next-generation ALKi [N=34, mOS: not reached (NR)] as the initial ALKi, compared with patients treated with conventional chemotherapy but no ALKi (N=36, mOS: 10.3 months, P

Aim: To investigate the efficacy, safety and optimal dosage of bevacizumab in non-squamous, non-small-cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE). Methods: 20 patients were enrolled and received intrapleural injection of bevacizumab (group A: 2.5 mg/kg d1, d8; group B: 5 mg/kg d1, d8; group C: 7.5 mg/kg d1, d8). Results: The objective response rate (ORR) of MPE was 50%. The median progression-free survival (PFS) of MPE was 7.0 months (95% CI 4.9–9.2). The ORR and PFS of MPE from group B were better than those of group A and group C. The most common adverse events (AEs) were hypertension (15%) and anemia (15%). Conclusion: Bevacizumab has certain efficacy in non-squamous NSCLC patients with MPE. Clinical Trial Registration: NCT02942043 ( ClinicalTrials.gov ).

OBJECTIVE: Atezolizumab along with chemotherapy has prolonged the survival of patients with extensive-stage small-cell lung cancer (ES-SCLC) worldwide, although real-world (RW) data are lacking in China. This study was designed to evaluate the efficacy and clinical outcomes of atezolizumab plus etoposide/platinum (EP). METHODS: Data obtained in this retrospective study were captured from six oncology units of five medical facilities from January 2019 to April 2022. For first-line treatments, atezolizumab combined with EP vs. EP alone, we primarily evaluated progression-free survival (PFS); other efficacy indicators, including overall survival (OS), objective response rate (ORR), and patterns of SCLC progression and adverse events (AEs) were assessed. RESULTS: The primary analysis included data from 225 patients, of whom 133 received EP along with atezolizumab (atezolizumab group) and 92 received EP alone (EP group). The PFS duration of the atezolizumab group [7.10 months; 95% confidence interval (95% CI), 6.53−9.00] exceeded that of the EP group (6.50 months; 95% CI, 4.83−7.53). Overall, the hazard ratio (HR) was 0.69 (95% CI, 0.49−0.97) (P=0.029); particularly, the HR was 0.54 (95% CI, 0.36−0.80) among patients undergoing ≥4 chemotherapy cycles and 0.33 (95% CI, 0.20−0.56) among individuals with atezolizumab maintenance. The ORR and disease-control rate (DCR) were similar between the two groups. Because of incomplete OS data, the median OS was not determined for either group. Bone marrow suppression was the most common AE detected (58.6%) in the atezolizumab group. Immune-related AEs occurred in 19 patients in the atezolizumab group (14.3%), with only one case of grade 3 encephalitis. CONCLUSIONS: This RW study in China demonstrated improved clinical outcomes of atezolizumab along with EP for ES-SCLC, particularly in the chemosensitive population. These results align with the results of the IMpower133 study, although the impact of this treatment modality on OS warrants additional follow-up studies.

Supplemental material, sj-docx-1-tct-10.1177_15330338211039676 for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study by Jie Zhang, Di Wu, Ziran Zhang, Jieran Long, Guangming Tian, Yang Wang, Xiangjuan Ma, Xiaoling Chen, Jindi Han, Weiheng Hu, Ling Dai, Jun Nie and Jian Fang in Technology in Cancer Research & Treatment

Supplemental material, sj-docx-2-tct-10.1177_15330338211039676 for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study by Jie Zhang, Di Wu, Ziran Zhang, Jieran Long, Guangming Tian, Yang Wang, Xiangjuan Ma, Xiaoling Chen, Jindi Han, Weiheng Hu, Ling Dai, Jun Nie and Jian Fang in Technology in Cancer Research & Treatment

Supplemental material, sj-docx-4-tct-10.1177_15330338211039676 for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study by Jie Zhang, Di Wu, Ziran Zhang, Jieran Long, Guangming Tian, Yang Wang, Xiangjuan Ma, Xiaoling Chen, Jindi Han, Weiheng Hu, Ling Dai, Jun Nie and Jian Fang in Technology in Cancer Research & Treatment

Supplemental material, sj-pdf-3-tct-10.1177_15330338211039676 for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study by Jie Zhang, Di Wu, Ziran Zhang, Jieran Long, Guangming Tian, Yang Wang, Xiangjuan Ma, Xiaoling Chen, Jindi Han, Weiheng Hu, Ling Dai, Jun Nie and Jian Fang in Technology in Cancer Research & Treatment